24 results about "Uveal tract" patented technology

Some embodiments of the invention advantageously leverage the expansion, dilation or by-pass of the Schlemm's canal using adjustable reversible self-expanding eye stents (SES) or eye tension rings (ETRs) of desired sizes to control and improve aqueous flow throughout the range of the uveolymphatic canal. As such, some embodiments include tension ring(s) or cylinders that sits either inside or outside the Schlemm's canal wall and is at least partially within the canal and / or is partially or fully anchored, attached, adhered, or otherwise held in place with respect to the wall and / or elsewhere in the canal. The partial or complete expansion of the canal can be pre-configured based on pre-operative metrology of the Schlemm's canal to a customized and adjustable fit across the various zones within the uveolymphatic canal and based on the patient specific and evolving needs. Additionally, the SES can utilize entry / exit features for by-pass of fluid, varying control of dilation across its shape that may also allow anchoring, repositioning, and retrieval.

The present invention provides a compound of Formula Iand pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The present application provides an acesulfame implant which is stable, safe and can achieve at least 6 months of sustained release, can effectively treat various eye diseases including but not limited to glaucoma, cataract, retinal vein obstruction (RVO), uveitis, diabetic macular edema (DME) and age-related macular degeneration (wAMD and nAMD), etc., avoids repeated administration, reduces the formation of side effects, reduces the cost of drug use, and meets the high stability required by drug preparation in production, storage and transportation, has good application prospect, and meets the unmet clinical needs.

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The present invention relates to superoxide dismutase and uses thereof for preventing or treating diabetic retinopathy or uveitis. The superoxide dismutase according to the present invention can be effectively used in the prevention or treatment of diabetic retinopathy or uveitis, particularly through oral administration.

The invention discloses application of oroxylum indicum total flavonoids in preparation of a medicine for treating uveitis. Experiments prove that the eye drops taking the oroxylum indicum total flavonoids or the oroxylin A as the active ingredient can reduce the uveitis eye inflammation and retina injury degree and reduce the infiltration quantity of inflammatory cells. The oroxylum indicum general flavone is taken as an oral medicine, so that inflammatory infiltration cells of a vitreous cavity and an iris-ciliary body can be reduced, bleeding symptoms can be effectively improved, hyperplasia of iris-ciliary body tissues can be inhibited, and infiltration of leukocytes of aqueous humor in mouse eyes can be effectively inhibited.

A non-invasive diagnostic system is disclosed that integrates Raman spectroscopy with Artificial Intelligence (AI) to detect, classify, and quantify biomarkers and pharmacologic agents in the aqueous humor of the anterior chamber of the eye. The system includes a handheld or slit lamp-mounted Raman probe, a spectral acquisition and preprocessing pipeline, and an AI analysis engine trained to recognize disease-associated molecular signatures. The platform supports real-time diagnosis of glaucoma, uveitis, and other anterior segment conditions, enabling early detection, risk stratification, and longitudinal monitoring. The AI component is capable of incorporating newly discovered biomarkers and contextual factors such as medication use, diurnal variation, and anatomical sampling location. Diagnostic outputs are presented with confidence scores and may include disease classification, biomarker trends, or pharmacologic exposure levels. Built-in safety protocols ensure ANSI Z136.1-compliant laser use, while explainable AI tools and federated learning enhance transparency and clinical adaptability.

The present disclosure relates to peptide compositions and methods for treating an inflammatory condition such as ocular inflammation, retinal inflammation, dry eye, uveitis, allergic conjunctivitis, and inflammation resulting from nerve injury or nerve degeneration. The peptide compositions disclosed herein can also be used for treating pain such as neuropathic pain, ocular pain, chronic pain, pain resulting from chemotherapy or radiation, pain resulting from nerve injury or nerve degeneration, and pain resulting from an inflammatory condition, dysesthesia, or allodynia.

The invention relates to an ophthalmic implant (20) for permanent insertion between sclera and uveal tissue, comprising a uveal compatible implant body (22) extending along a main axis (A) intended to be oriented in an anterior-posterior direction, the implant body comprises an upper surface (32) intended to face the sclera and a lower surface (34) intended to come into contact with the uveal tissue, the implant body further comprising a first edge (24), referred to as the anterior edge, intended to be oriented towards the anterior chamber of the eye and a second edge (26), referred to as the posterior edge, opposite the anterior edge relative to the implant body. The lower surface is smooth, and the implant body includes one or more protrusions (36) extending from the upper surface toward the exterior of the body to allow the one or more protrusions to contact the sclera and to separate the sclera from the upper surface of the implant body.

The present invention relates to a sterile ophthalmic composition comprising castor oil and medium-chain triglycerides; to the use of said composition in medicine, in particular for the treatment and / or prevention of an ocular disease selected from the group consisting of dry eye, conjunctivitis, dermatitis, blepharitis, entropion, lax eye lid syndrome, thyroid eye disease, pterygium, conjunctival laxity, epithelial damage caused by preservatives, epithelial or anterior chamber damage caused by ocular surgery, corneal limbal cell deficiency, corneal ulceration caused by physical or chemical agents, keratitis, sub-scleritis and uveitis.

A stent implant for treating glaucoma by intraocular fluid drainage from the anterior chamber, for example into the suprachoroidal space. The stent implant is designed to change in shape after being inserted into the eye, during which change the width and / or thickness or the flow cross-section is increased by for example 20%, in another example more than 200%, and in a further example by more than 400%, at least one point of the stent implant. In the case of intraocular fluid drainage from the anterior chamber into the suprachoroidal space, a cyclodialysis cleft which may open can be largely or completely closed. With appropriate adjustments, the stent implant can also be applied in trabecular, uveoscleral, uveolymphatic and subconjunctival applications for intraocular fluid drainage from the anterior chamber. The implant can even be used for direct intraocular fluid discharge from the anterior chamber onto the surface of the eye.

The application discloses a traditional Chinese medicine composition for treating non-infectious uveitis of heat-toxin entering collaterals syndrome and a traditional Chinese medicine preparation and application thereof. According to weight parts, raw medicinal materials of the traditional Chinese medicine composition include 6-30 parts of honeysuckle, 9-30 parts of figwort, 6-20 parts of angelica, 2-10 parts of raw licorice, 6-15 parts of red peony root, 3-10 parts of chuanxiong rhizome, 5-15 parts of radix paeoniae alba, 6-20 parts of radix rehmanniae recens and 3-15 parts of dried tangerine or orange peel. Based on the theory of collaterals disease, the traditional Chinese medicine composition provided by the application is used for treating non-infectious uveitis of heat-toxin entering collaterals syndrome with heat-clearing, detoxifying and collaterals-unblocking as a basic rule. When the traditional Chinese medicine composition is combined with basic western medicine for treating non-infectious uveitis, the traditional Chinese medicine composition can not only effectively treat non-infectious uveitis and reduce the recurrence rate of non-infectious uveitis within 6 months, but also accelerate the relief of eye symptoms, accelerate the recovery of eyesight and reduce the toxic side effects of combined hormone medication.

This utility model discloses a simulated eyeball for ophthalmic surgical demonstrations, comprising a spherical shell formed by splicing two hemispherical shells. The spherical shell includes a scleral simulated shell, an uveal simulated shell, and a retinal simulated shell. At designated locations inside the front end of the spherical shell are simulated structures for the iris, ciliary processes, lens, and suspensory ligaments. The circular hole in the center of the iris simulated structure serves as a simulated pupil. Through its unique three-layer shell design, from the outer scleral simulated shell to the inner uveal and retinal simulated shells, the simulated eyeball accurately reproduces the complex hierarchical structure of the human eye. In particular, the simulated structures within the eyeball, such as the iris, ciliary processes, lens, suspensory ligaments, and pupil, allow trainees to intuitively familiarize themselves with the key internal structures of the eyeball during demonstrations, providing accurate references for surgical procedures and significantly improving the demonstration effect.

The invention provides nano-particles of SPHK1 coated by a macrophage membrane and application of the nano-particles in experimental autoimmune uveitis, and relates to the technical field of new drug development. The preparation method comprises the following steps: loading SPHK1 expression plasmids driven by a TBG promoter by using a polylactic acid-glycolic acid copolymer (PLGA) as a nano-carrier, and then coating the SPHK1 expression plasmids with a macrophage membrane stimulated by lipopolysaccharide to prepare LPS-MM / PLGA-mSPHK1. According to the invention, LPS-MM / PLGA-mSPHK1 can be recruited to a retinopathy site, so that accumulation of the LPS-MM / PLGA-mSPHK1 in the retinopathy site is increased, the gene intervention effect is enhanced, the efficient uveitis lesion site targeting function is realized, retinal injury and inflammatory response can be relieved, retinal barrier injury is prevented, and good biological safety is achieved.

The invention discloses an exosome protein as a molecular marker for diagnosing uveitis, and belongs to the technical field of molecular diagnos.The molecular marker is isocitrate dehydrogenase 3a (IDH3a) protein in exosomes, and the sequence of the isocitrate dehydrogenase 3a (IDH3a) protein is shown as SEQ ID NO.1. The molecular marker has the advantages of being high in non-invasiveness, high in specificity and sensitivity, easy and convenient to operate, low in cost and the like, early screening can be achieved, and the application prospect is wide. And the method is suitable for popularization and application in clinical laboratories.

The present invention provides compounds of Formula (I) and pharmaceutical compositions comprising one or more of the compounds, and methods of using the compounds to treat or prevent one or more conditions that can benefit from the inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age-related macular edema, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The invention relates to the field of medicine, namely to ophthalmology, and can be used in the combined treatment of active retinopathy of prematurity type 1 in zone 1, in children with a gestational age of less than 28 weeks. The technical objective is to develop an effective method for the combined treatment of active retinopathy of prematurity type 1 in zone 1, in children with a gestational age of less than 28 weeks, by performing simultaneous transpupillary laser coagulation of the retina only in the nasal quadrants and introducing an angiogenesis inhibitor into the vitreous cavity. The proposed method solves this problem, involving simultaneous transpupillary laser photocoagulation of avascular zones of the retina in the nasal quadrants only and the injection of an angiogenesis inhibitor into the vitreous cavity. This method prevents the development of tractional retinal detachment, which causes blindness and low vision in children, reactivation of active ROP, and postoperative uveitis, which require additional surgical treatment, in 100% of cases.